



ASX ANNOUNCEMENT

13 July 2015

Shareholder Update: QUT transfers ownership of IP to Tissue Therapies

- Tissue Therapies signs agreement with Queensland University of Technology (QUT)
 - Absolute ownership of all intellectual property (IP) assigned to Tissue Therapies
 - IP under five patent families included in the agreement
 - Agreement strengthens the Company's commercial position

Brisbane, 13 July 2015: Tissue Therapies (ASX:TIS), a biomedical technology company developing effective treatments for wound healing, announces today that it has secured ownership of all intellectual property around its VitroGro® ECM therapeutic application.

Tissue Therapies Interim CEO, Mr Nigel Johnson, said: "I am delighted to announce that Tissue Therapies now has full ownership of its entire IP portfolio. We are aware of the importance of this agreement to shareholders and potential partners, and sought to agree this changed arrangement with QUT to strengthen our current position."

"Securing ownership of the IP around our lead application, VitroGro® ECM, will provide the market with more certainty around the Company's assets and commercial potential."

"I would like to thank QUT for its ongoing professionalism and guidance, and look forward to continuing our mutually beneficial long-term relationship."

In June, Tissue Therapies announced that the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) had accepted a revised plan for the development of VitroGro® ECM, confirming a viable pathway for taking VitroGro® ECM to market in Europe as a medical device.

This changed arrangement with QUT forms part of a comprehensive operational review led by Interim Chairman, Dr Cherrell Hirst and Mr Nigel Johnson that is progressing well and nearing completion.

VitroGro® ECM has been developed for use in the management of chronic wounds, in particular chronic venous leg ulcers, that do not follow the normal processes of wound repair and that have been present for more than four weeks despite standard care.

Chronic wounds are characterised by a dysfunctional extracellular matrix (ECM) which blocks the movement of repair cells to the site. VitroGro® ECM is administered topically to the wound bed and



acts as a replacement ECM, allowing repair cells to attach, migrate, and proliferate, leading to tissue regeneration and, ultimately, wound closure.

- ENDS -

For more information

Dr Cherrell Hirst, Chairman Tissue Therapies Limited Cherrell@hirst.com Nigel Johnson, CEO Tissue Therapies Limited Tel: +61 7 3334 3900 Email: n.johnson@tissuetherapies.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au
--	--

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.

Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company also has a license for commercialisation of various patent families related to wound healing and other therapeutic uses. Tissue Therapies Limited's shares are traded on the Australia, Berlin and Frankfurt stock exchanges. For more information, please visit www.tissuetherapies.com.